Combination pharmacotherapy for stopping smoking: What advantages does it offer?

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Globally, tobacco kills almost 5 million people around the world annually. Seven first-line pharmacotherapies are currently available and recommended by the United States Public Health Service (USPHS) clinical practice guideline for treating tobacco dependence, all of which have been proven to be effective for increasing tobacco abstinence rates when used as monotherapy. However, not all smokers are able to quit with single-drug therapy. Some smokers may benefit from combination therapy that includes the simultaneous use of different nicotine replacement therapies (NRTs) or medications with different mechanisms of action (e.g. NRT and bupropion). Combination therapy with different types of NRT may provide a therapeutic advantage by increasing serum nicotine concentrations, and combination therapy with different drugs may capitalize on synergy obtained from two different mechanisms of action. However, controversy exists regarding this approach. Available data suggests that combination therapy may increase abstinence rates compared with monotherapy. However, the cost effectiveness of this approach has not been clearly demonstrated.

Original languageEnglish (US)
Pages (from-to)643-650
Number of pages8
JournalDrugs
Volume70
Issue number6
DOIs
StatePublished - 2010

Fingerprint

Smoking
Drug Therapy
Nicotine
Therapeutics
Tobacco
Bupropion
Tobacco Use Disorder
United States Public Health Service
Practice Guidelines
Cost-Benefit Analysis
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Combination pharmacotherapy for stopping smoking : What advantages does it offer? / Ebbert, Jon Owen; Hays, James Taylor; Hurt, Richard D.

In: Drugs, Vol. 70, No. 6, 2010, p. 643-650.

Research output: Contribution to journalArticle

@article{b14b8362fbc148a98bfb8f82306e7348,
title = "Combination pharmacotherapy for stopping smoking: What advantages does it offer?",
abstract = "Globally, tobacco kills almost 5 million people around the world annually. Seven first-line pharmacotherapies are currently available and recommended by the United States Public Health Service (USPHS) clinical practice guideline for treating tobacco dependence, all of which have been proven to be effective for increasing tobacco abstinence rates when used as monotherapy. However, not all smokers are able to quit with single-drug therapy. Some smokers may benefit from combination therapy that includes the simultaneous use of different nicotine replacement therapies (NRTs) or medications with different mechanisms of action (e.g. NRT and bupropion). Combination therapy with different types of NRT may provide a therapeutic advantage by increasing serum nicotine concentrations, and combination therapy with different drugs may capitalize on synergy obtained from two different mechanisms of action. However, controversy exists regarding this approach. Available data suggests that combination therapy may increase abstinence rates compared with monotherapy. However, the cost effectiveness of this approach has not been clearly demonstrated.",
author = "Ebbert, {Jon Owen} and Hays, {James Taylor} and Hurt, {Richard D.}",
year = "2010",
doi = "10.2165/11536100-000000000-00000",
language = "English (US)",
volume = "70",
pages = "643--650",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Combination pharmacotherapy for stopping smoking

T2 - What advantages does it offer?

AU - Ebbert, Jon Owen

AU - Hays, James Taylor

AU - Hurt, Richard D.

PY - 2010

Y1 - 2010

N2 - Globally, tobacco kills almost 5 million people around the world annually. Seven first-line pharmacotherapies are currently available and recommended by the United States Public Health Service (USPHS) clinical practice guideline for treating tobacco dependence, all of which have been proven to be effective for increasing tobacco abstinence rates when used as monotherapy. However, not all smokers are able to quit with single-drug therapy. Some smokers may benefit from combination therapy that includes the simultaneous use of different nicotine replacement therapies (NRTs) or medications with different mechanisms of action (e.g. NRT and bupropion). Combination therapy with different types of NRT may provide a therapeutic advantage by increasing serum nicotine concentrations, and combination therapy with different drugs may capitalize on synergy obtained from two different mechanisms of action. However, controversy exists regarding this approach. Available data suggests that combination therapy may increase abstinence rates compared with monotherapy. However, the cost effectiveness of this approach has not been clearly demonstrated.

AB - Globally, tobacco kills almost 5 million people around the world annually. Seven first-line pharmacotherapies are currently available and recommended by the United States Public Health Service (USPHS) clinical practice guideline for treating tobacco dependence, all of which have been proven to be effective for increasing tobacco abstinence rates when used as monotherapy. However, not all smokers are able to quit with single-drug therapy. Some smokers may benefit from combination therapy that includes the simultaneous use of different nicotine replacement therapies (NRTs) or medications with different mechanisms of action (e.g. NRT and bupropion). Combination therapy with different types of NRT may provide a therapeutic advantage by increasing serum nicotine concentrations, and combination therapy with different drugs may capitalize on synergy obtained from two different mechanisms of action. However, controversy exists regarding this approach. Available data suggests that combination therapy may increase abstinence rates compared with monotherapy. However, the cost effectiveness of this approach has not been clearly demonstrated.

UR - http://www.scopus.com/inward/record.url?scp=77951044898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951044898&partnerID=8YFLogxK

U2 - 10.2165/11536100-000000000-00000

DO - 10.2165/11536100-000000000-00000

M3 - Article

C2 - 20394453

AN - SCOPUS:77951044898

VL - 70

SP - 643

EP - 650

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 6

ER -